Key Opinion Leader (KOL) in Pharmaceutical Business Intelligence – Aviva Lev-Ari, PhD, RN, as Evidenced by
Curator: Aviva Lev-Ari, PhD, RN
UPDATED on 4/4/2022
Analytics for e-Reputation based on LinkedIn 1st Degree Connections, +7,500 of LPBI Group’s Founder, 2012-2022: An Intangible Asset – Connections’ Position Seniority & Biotech / Pharma Focus
Author: Aviva Lev-Ari, PhD, RN, Founder of 1.0 LPBI, 2012-2020 & 2.0 LPBI, 2021-2025 and Data Scientist, Research Assistant III: Tianzuo George Li
-
e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point
-
Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018
WE ARE ON AMAZON.COM – 1/1/2018 – 13 e-Books in Medicine and Life Sciences
http://www.amazon.com/dp/B00DINFFYC
http://www.amazon.com/dp/B018Q5MCN8
http://www.amazon.com/dp/B018PNHJ84
http://www.amazon.com/dp/B018DHBUO6
http://www.amazon.com/dp/B013RVYR2K
http://www.amazon.com/dp/B012BB0ZF0
http://www.amazon.com/dp/B019UM909A
http://www.amazon.com/dp/B019VH97LU
http://www.amazon.com/dp/B071VQ6YYK
https://www.amazon.com/dp/B075CXHY1B
https://www.amazon.com/dp/B076HGB6MZ
https://www.amazon.com/dp/B078313281
https://www.amazon.com/dp/B078QVDV2W
13 results for Kindle Store :
FIVE years of e-Scientific Publishing @pharmaceuticalintellicence.com, Top Articles by Author and by e-Views >1,000, 4/27/2012 to 1/29/2018
Editor-in-Chief: Aviva Lev-Ari, PhD, RN
Top Authors, by +5 years of e-Views, 1/29/2018, on pharmaceuticalintelligence.com
Editor-in-Chief: Aviva Lev-Ari, PhD, RN
Digital Presence measured by eViews: Clicks on articles by Author Name
Top Authors for all days ending 2018-05-28 (Summarized)
1. Our 15 e-Books in Genomics and Medicine were on Display at the Publication Desk of CHI @CHI’s 14th Annual Discovery on Target took place September 19 – 22, 2016 in Boston, Westin Boston Waterfront
2. New e-Book TITLES forthcoming on Amazon.com in 2018 from LPBI Group’s BioMed e-Series
Work-in-Progress
Work-in-Progress
- Genomics Volume 2: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology
Work-in-Progress
3. June 19, 2016 – We Celebrate reaching over One Million e-Readers @PharmaceuticalIntelligence.com
4. Founder
https://pharmaceuticalintelligence.com/founder/
5. Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence: Contributions of Aviva Lev-Ari, PhD, RN
6. Corporate Clients for our Services: Funding Medical Devices Development & Biologics
https://pharmaceuticalintelligence.com/joint-ventures/corporate-clients-for-our-services/
7. REAL TIME Press Coverage for Biotech and Medicine, Scientific and Business Investment International Conferences
List of Conferences Covered in Real Time by
Aviva Lev-Ari, PhD, RN on Press Pass, 2013 – Present
Year |
# Conferences covered in Real Time |
Conference Organizers |
2020 |
||
2019 |
||
2018 |
10 |
MassBio, AI,ML&CL, MassBio-Devices&Drugs, WMIF-AI-Partners, US-India BioPharma, BioIT, BIO 2018!, Koch@MIT, , CHI-DiscoveryonTarget, PMC-HMS |
2017 |
12 |
MassBio, WMIF-CVD-Partners, US-India BioPharma, BioIT, Koch@MIT, CHI-IO CHI OncoVirus IO, WarrenLecture-HMS, HubWeek, Koch@MIT, EmTech@MIT, PMC-HMS |
2016 |
8 |
MassBio, WMIF-Cancer-Partners, US-IndiaBioPharma, CHI-IO, CHI-OncoVirus IO, CHI DiscoveryonTarget, EmTech @MIT, PMC-HMS |
2015 |
5 |
PMWC-SiliconVallley, MassBio, BioIT, EmTech@MIT, PMC-HMS, |
2014 |
7 |
SacksAssoc-NY, MassBio, BioIT Koch@MIT, SacksAssoc-Basel, Brandeis, PMC-HMS, |
2013 | 1 |
BioIT |
https://pharmaceuticalintelligence.com/press-coverage/
8. Social Media Influence and Channels for Content e-Marketing
-
Our Journal has 1,436,050 eReaders, 2,339 subscribers and 7,291 Scientific Comments on 28/5/2018, for All Time, 28/4/2012 – 28/5/2018
http://pharmaceuticalintelligence.com
- Aviva has +6,592 BIOTECH Followers on LinkedIn
http://www.linkedin.com/in/avivalevari
- Aviva is a Member of +60 LinkedIn Groups in Biotech-related fields
https://www.linkedin.com/groups/my-groups
- LPBI Group’s FaceBook Page
http://www.facebook.com/LeadersInPharmaceuticalBusinessIntelligence
- LPBI Group’s Twitter Account with hundreds of followers
- Aviva is a LinkedIn (LI) Group Launcher and Manager of Three LI Groups
Cardiovascular Biotech & Pharma UK & US Networking Group
918 members (1/2018)Leaders in Pharmaceutical Business Intelligence
344 members (1/2018)Innovation in Israel
191 members (1/2018)
- LPBI Group’s Company’s Page on LinkedIn
Additional LINKS on Professional Activities as Parameters of the Key Opinion Leader
-
Scientific and Medical Affairs Chronological CV
-
HealthCare Delivery – Long Term Post Acute Care Nursing Management CV
-
Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence
-
List of Publications, 2006 – Present
-
Cardiovascular Diseases and Pharmacological Therapy: Curations, 2006 – 4/2018
-
MedTech & Medical Devices for Cardiovascular Repair – Curations
-
Stem Cells and Cardiac Repair: Content Curation & Scientific Reporting
-
Regulatory Affairs: Publications on FDA-related Issues – Aviva Lev-Ari, PhD, RN
-
Cancer Research: Curations and Reporting
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.